GIP

GIP. Gastric inhibitory polypeptide, now more commonly referred to as glucose-dependent insulinotropic polypeptide, is a significant enteroendocrine hormone produced by K cells located in the mucosa of the duodenum and jejunum. It plays a crucial role in the incretin effect, a physiological process whereby hormones secreted from the gut potentiate glucose-stimulated insulin secretion from the pancreatic beta cells. The discovery and characterization of GIP have profoundly influenced the understanding of postprandial physiology and the development of novel therapeutics for metabolic disorders.

Function and physiology

GIP is released into the circulatory system in response to the ingestion of nutrients, particularly glucose and fatty acids. Its primary physiological action is to augment insulin release from the pancreatic islets in a glucose-dependent manner, meaning its effect is potent only when blood sugar levels are elevated. Beyond its insulinotropic effects, GIP influences lipid metabolism by promoting fatty acid incorporation into adipose tissue and may modulate bone turnover through effects on osteoblasts and osteoclasts. The hormone also exhibits actions on the gastrointestinal tract, initially thought to inhibit gastric acid secretion, which contributed to its original name.

Receptor and signaling

The biological effects of GIP are mediated through its specific, high-affinity G protein-coupled receptor, known as the GIP receptor (GIPR). The GIPR is predominantly expressed on pancreatic beta cells and adipocytes, but is also found in the brain, heart, and adrenal cortex. Upon binding, the receptor primarily activates the Gs alpha subunit, leading to increased intracellular cyclic AMP (cAMP) levels and activation of protein kinase A (PKA). This signaling cascade ultimately results in the exocytosis of insulin granules. The GIPR is a member of the secretin receptor family and shares structural homology with the receptor for the other major incretin hormone, glucagon-like peptide-1 (GLP-1).

Role in metabolism and disease

In the context of type 2 diabetes mellitus, the insulinotropic response to GIP is markedly diminished or absent, a phenomenon known as incretin resistance. This defect is considered a key contributor to the impaired postprandial insulin secretion observed in the disease. Conversely, in conditions of obesity, GIP secretion and action on adipose tissue are often enhanced, which may promote adiposity and weight gain. Research also explores potential links between GIP and other conditions, including cardiovascular disease and polycystic ovary syndrome (PCOS), given its receptors in relevant tissues like the endothelium and ovaries.

Therapeutic applications

Given its reduced efficacy in type 2 diabetes, native GIP itself is not used therapeutically. However, understanding its role has been pivotal in drug development. A major breakthrough has been the creation of tirzepatide, a novel dual agonist that activates both the GIP receptor and the GLP-1 receptor. Clinical trials, such as the SURPASS program, have demonstrated that tirzepatide is highly effective at lowering HbA1c and promoting weight loss, outperforming selective GLP-1 receptor agonists like semaglutide. This success has validated the therapeutic potential of co-activating the GIP pathway and spurred further research into other multi-agonists.

Research and clinical significance

Ongoing research investigates the full spectrum of GIP's actions, including its effects on the central nervous system, where it may influence appetite regulation and cognitive function. Studies using GIP receptor antagonists and GIP receptor knockout mice help delineate its physiological and pathophysiological roles. The clinical significance of GIP extends beyond diabetology into areas like osteoporosis and Alzheimer's disease, given its anabolic effects on bone and potential neuroprotective properties. The evolution from considering GIP as a mere gut hormone to recognizing it as a key systemic regulator underscores its importance in integrative physiology and precision medicine.

Category:Peptide hormones Category:Digestive system Category:Diabetes